The cGAS pathway is normally activated when DNA appears in the wrong cellular compartment. In healthy cells, most DNA is confined to the nucleus and mitochondria. DNA fragments released during infection, cellular stress or tissue damage can instead accumulate in the cytoplasm, where cGAS binds them and produces the signalling molecule cyclic GMP–AMP. This molecule activates the adaptor protein STING, which then triggers a cascade of kinases and transcription factors, including IRF3 and NF-κB. The result is production of type I interferons and other inflammatory mediators. That response is valuable against certain pathogens, but excessive or chronically activated signalling can disrupt tissue function. The new work suggests that in the intestine, this defensive circuitry has consequences far beyond local immunity, influencing the metabolic conversation between the gut microbiota and adipose tissue.

The researchers found evidence that intestinal cGAS signalling is heightened in obesity. Their analysis indicated activation of the pathway in intestinal samples from humans with obesity and in male mice exposed to a high-calorie diet. Increased signalling was accompanied by greater expression of type I interferons and signs of heightened immune activity among intestinal cells. Type I interferons are powerful antiviral cytokines that change gene expression across many cell types, preparing tissues to respond to infection. However, persistent interferon activity can also reshape epithelial biology, alter interactions with resident microbes and affect the production or handling of small molecules generated in the gut. The observations do not suggest that cGAS is the sole cause of obesity, but they identify it as a potentially important biological response to the intestinal stress associated with excess nutrition.

To test whether the pathway was merely correlated with obesity or actively contributed to it, the investigators deleted the cGAS gene in intestinal epithelial cells. These cells form the gut lining and represent a critical interface between food, microbes and the immune system. They absorb nutrients, maintain the intestinal barrier and release signals that influence organs elsewhere in the body. Mice lacking cGAS in this compartment were protected from diet-induced weight gain despite consuming an obesity-promoting diet. The animals also showed increased energy expenditure, meaning they used more energy over time rather than simply absorbing fewer calories. Their metabolic profiles improved as well, indicating benefits that extended beyond body weight. Because cGAS was removed selectively from the intestinal epithelium, the results highlight the gut lining as a signalling hub rather than implying that global inhibition of cGAS would produce the same effects.

The mechanism depended on the gut microbiota, the dense community of microorganisms that transforms dietary compounds and releases metabolites into the intestinal environment and circulation. When the researchers disrupted or altered the microbiota, the protective metabolic effects of intestinal cGAS deletion were diminished. This finding places bacteria between the intestinal immune sensor and the body’s energy-burning machinery. The study identified Lactobacillus murinus as a particularly important member of this microbial network. In the absence of intestinal epithelial cGAS, the abundance or activity of this bacterium was associated with increased production of indole-3-acetic acid, commonly known as IAA. IAA is an indole-derived metabolite generated from tryptophan by microbial metabolism. Although it is chemically related to plant auxins, in mammals it can act as a signalling molecule capable of influencing immune and metabolic pathways.

According to the study, IAA was a key messenger in the gut-to-adipose effect. The metabolite promoted thermogenesis, the process by which specialized fat cells convert stored chemical energy into heat. This function is most strongly associated with brown and beige adipose tissue, where mitochondria contain uncoupling protein 1, or UCP1. UCP1 dissipates the proton gradient normally used to generate ATP, releasing energy as heat instead. Increased thermogenesis raises total energy expenditure and can counter the accumulation of fat during excess caloric intake. The findings suggest that intestinal cGAS–STING–interferon activity suppresses this beneficial microbial output, while removing cGAS allows an L. murinus–IAA axis to become more active and stimulate heat-producing fat. In this model, an immune signal in the intestine changes microbial chemistry, and that chemistry alters the behaviour of adipose tissue.

The study’s implications extend beyond a simple relationship between inflammation and weight gain. The intestine must continuously distinguish harmless dietary and microbial signals from genuine danger, and cGAS is part of the molecular machinery that makes those judgements. Nutrient overload, epithelial stress and changes in microbial communities may increase the amount of DNA or DNA-like material sensed by the pathway, producing interferon responses that are appropriate in some circumstances but metabolically costly when sustained. By reducing the availability of IAA, chronic intestinal cGAS activity could weaken thermogenic capacity and favour energy storage. This proposed circuit offers a possible explanation for how local immune activation contributes to systemic metabolic disease without requiring inflammation to begin in adipose tissue itself.

The researchers caution, however, that the findings currently provide a stronger mechanistic case in male mice than in humans. The human observations show that intestinal cGAS signalling is activated in people with obesity, but they do not establish that blocking the pathway would cause weight loss or improve metabolic disease in patients. Sex, age, diet, genetics and the composition of the microbiota could all affect the pathway, and the study’s central animal experiments were conducted in males. IAA is also not a universal therapeutic answer: its effects may depend on dose, tissue exposure, receptor signalling and the wider microbial community in which it is produced. Manipulating L. murinus or administering IAA would require careful testing for safety, durability and unintended effects on immunity.

Even with those limitations, the work identifies a striking therapeutic concept: treating obesity by rewiring an immune–microbial–metabolic circuit in the intestine. Future strategies could seek to inhibit cGAS or STING selectively in intestinal epithelial cells, temper excessive type I interferon signalling, support beneficial microbial producers of IAA or deliver metabolites that enhance adipose thermogenesis. Such approaches would need to preserve the essential infection-fighting functions of cGAS while avoiding systemic immune suppression. The study by Deng, Meng, Yang and colleagues therefore adds the intestinal lining to the growing list of tissues that can control whole-body energy balance. It also reinforces a broader lesson of modern metabolic biology: the route to healthier fat may begin not in fat itself, but in the molecular dialogue between gut cells and the microbes living alongside them.

Subject of Research: Intestinal cGAS–STING–type I interferon signalling, gut microbiota, indole-3-acetic acid and obesity-related energy metabolism.

Article Title: Intestinal cGAS–STING–IFN signalling promotes obesity by downregulating microbiota-derived IAA in male mice.

Article References: Deng, J., Meng, W., Yang, Y. et al. “Intestinal cGAS–STING–IFN signalling promotes obesity by downregulating microbiota-derived IAA in male mice.” Nature Metabolism 8, 1713–1729 (2026). https://doi.org/10.1038/s42255-026-01562-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01562-4

Keywords: cGAS, STING, type I interferon, intestinal epithelium, obesity, gut microbiota, Lactobacillus murinus, indole-3-acetic acid, IAA, adipose thermogenesis, energy expenditure.

At the forefront of tonic signaling is leptin, a peptide hormone secreted primarily by adipose tissue. It acts as a steady, baseline indicator of the body’s energy stores, directly informing the brain about overall energy balance. Through its interaction with areas such as the arcuate nucleus, leptin influences appetite suppression and energy utilization, thereby maintaining homeostasis over chronic periods. In contrast, peptides like ghrelin, cholecystokinin (CCK), gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) execute their effects episodically, rapidly modulating feeding behaviors and digestive processes in response to specific meals.

Among these, ghrelin stands out for its unique biochemistry and function. Synthesized predominantly in the stomach, ghrelin is a 28-amino acid peptide, distinguished by an O-acyl modification at its serine residue, a feature critical for its biological activity. This post-translational acylation, catalyzed by ghrelin O-acyltransferase, enables the peptide to bind its receptor, triggering appetite-stimulating effects. Importantly, ghrelin circulates in two main forms: acylated ghrelin (AG), which is bioactive, and unacylated ghrelin (UAG), which lacks similar receptor affinity and exhibits divergent effects. Consequently, accurate measurement of AG in research requires meticulous sample handling to preserve the labile octanoyl group, a moiety prone to rapid degradation by proteases both in vivo and ex vivo.

The challenge posed by ghrelin’s instability has spurred comprehensive investigations into optimal blood sampling and processing techniques. Studies underscore the necessity of immediate cooling of blood samples, pre-chilling collection tubes, and rapid refrigerated centrifugation to prevent deacylation. Additionally, incorporation of protease inhibitors directly into collection tubes ensures immediate neutralization of degrading enzymes, safeguarding peptide integrity. For certain assays, acidification of samples with hydrochloric acid further stabilizes acylated ghrelin during long-term storage and repeated freeze-thaw cycles, highlighting the intricate balance required between biological nuance and laboratory precision.

Parallel to ghrelin, incretin hormones GIP and GLP-1 command vital roles in nutrient-induced insulin secretion and appetite regulation. GIP, secreted primarily by the small intestine, exists predominantly as the intact 42-amino acid peptide (GIP1-42), rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) into its inactive form GIP3-42. This rapid enzymatic conversion results in a circulating pool where the metabolite predominates, posing analytical challenges. Current consensus recommends measurement of “total GIP” to approximate secretory responses, while selectively analyzing the intact form may be necessary when endocrine-specific dynamics are under scrutiny.

GLP-1 shares a similar dual existence, secreted in two intact isoforms: GLP-1(7-37) with a glycine extension and amidated GLP-1(7-36) amide, with the latter predominating in human circulation. Its fleeting half-life, estimated at 1 to 2 minutes due to swift DPP-4 degradation into GLP-1(9-37) and GLP-1(9-36) amide metabolites, complicates peripheral measurement. Remarkably, only a small fraction of secreted GLP-1 reaches the venous circulation intact, with its primary satiety effects mediated via vagal nerve afferents before rapid degradation ensues. Despite early beliefs regarding the inactivity of its degraded metabolites, emerging evidence suggests these fragments may possess biological significance, opening new avenues for metabolic research.

Methodological rigor remains paramount when quantifying GIP and GLP-1. To prevent ex vivo peptide degradation during blood sampling, addition of DPP-4 inhibitors into collection tubes is standard. Techniques such as ethanol precipitation or solid-phase extraction further refine sample purity by reducing interference from plasma proteins, yielding more reproducible measures of active hormone concentrations. Intriguingly, while protease inhibitors like aprotinin were conventionally used to maintain peptide stability, recent evidence indicates that EDTA-coated tubes—even lacking these inhibitors—may suffice in tightly controlled clinical trial settings, provided that samples are processed promptly.

Assay variability poses another layer of complexity. Comparative assessments between commercially available enzyme-linked immunosorbent assays (ELISAs) and traditional radioimmunoassays (RIAs) reveal substantial discrepancies in sensitivity and specificity across different platforms and even batches. Therefore, researchers must carefully select assays with high fidelity tailored to the isoforms of interest and maintain analytical consistency within studies. The recent identification of a shorter GIP peptide variant (GIP1-30 amide) with potential biological activity—but not detected by most assays—further underscores the evolving landscape and the need for assay development that captures the full peptide spectrum.

Peptide YY (PYY), secreted chiefly from distal intestinal L-cells, exists mainly as full-length PYY1-36 and truncated PYY3-36, the latter generated through DPP-4-mediated cleavage. This truncation is critical; only PYY3-36 exerts potent appetite-suppressing effects by selectively activating the neuropeptide Y (NPY) Y2 receptor within the hypothalamus. Consequently, sample handling methodologies must prevent ex vivo conversion and proteolytic degradation beyond PYY3-36, ensuring accurate representation of biologically active forms.

Manufacturers often recommend the proactive addition of DPP-4 inhibitors and broad-spectrum protease inhibitors like aprotinin during blood collection to preserve PYY integrity. In practice, blood may be drawn into syringes containing DPP-4 inhibitors followed by aprotinin treatment, thereby arresting post-collection enzymatic activity. However, some studies suggest that the rapidity of sample processing itself may mitigate peptide breakdown, casting doubt on the universal necessity of such inhibitors in every context. Notably, EDTA combined with aprotinin treatment effectively prevents degradation of PYY3-36 into inactive PYY3-34 fragments, emphasizing tailored approaches based on research objectives.

Where direct quantification of PYY3-36 is unattainable, total PYY measurements serve as a pragmatic proxy due to generally parallel secretion patterns of PYY1-36 and PYY3-36 across feeding states. Nonetheless, situations exist where the ratio between these forms shifts, potentially distorting interpretations if isoform-specific analysis is neglected. Hence, prioritization of PYY3-36 assays is crucial in investigations aiming to dissect the precise appetite-modulating contributions of this peptide.

Collectively, these insights affirm that the measurement of appetite-related peptides, though laden with methodological intricacies, is indispensable for unraveling the neuroendocrine regulation of feeding and metabolism. Precision in sample handling, inhibitor selection, assay choice, and timing is vital to accurately capture the dynamic milieu of these hormones, thereby enhancing reproducibility and interpretability across studies. This knowledge is foundational not only for basic physiological inquiry but also for the development of therapeutic strategies targeting obesity, diabetes, and related metabolic disorders.

Moreover, the complexity inherent to peptide isoforms, rapid enzymatic degradation, and tissue-specific secretion profiles reflects the exquisite biological tuning that underpins appetite regulation. Future research harnessing advances in analytical chemistry and molecular biology promises to refine measurement techniques further, elucidating nuanced pathways and opening avenues for personalized interventions. As such, appetite-related peptides represent a captivating frontier in metabolic science, bridging molecular detail with systemic health implications.

Understanding these neurohumoral messengers thus transcends mere academic interest, holding transformative potential for nutritional science, clinical diagnostics, and pharmacological innovation. The evolving toolkit for their assessment exemplifies the synergy of technological prowess and biological insight, charting new terrain in the quest to decode the molecular language of hunger and satiety.

Subject of Research:
Appetite-related peptides and their neurohumoral role in regulating food intake and energy expenditure, with methodological considerations for their measurement.

Article Title:
The mixed-meal tolerance test as an appetite assay: methodological and practical considerations

Article References:
King, J.A., Thackray, A.E., Gibbons, C. et al. The mixed-meal tolerance test as an appetite assay: methodological and practical considerations. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01866-7

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41366-025-01866-7

Keywords:
Appetite peptides, ghrelin, leptin, GIP, GLP-1, PYY, energy balance, neurohumoral control, metabolic regulation, hormone assay methodologies, peptide stability, protease inhibitors